MX2023005889A - Inhibidor de integrina y usos de este. - Google Patents
Inhibidor de integrina y usos de este.Info
- Publication number
- MX2023005889A MX2023005889A MX2023005889A MX2023005889A MX2023005889A MX 2023005889 A MX2023005889 A MX 2023005889A MX 2023005889 A MX2023005889 A MX 2023005889A MX 2023005889 A MX2023005889 A MX 2023005889A MX 2023005889 A MX2023005889 A MX 2023005889A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- methods
- inhibitors
- integrin inhibitor
- integrin
- Prior art date
Links
- 229940125798 integrin inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002411 thermogravimetry Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente descripción se proporcionan inhibidores de integrina, composiciones de estos, y métodos para su uso. También se describen formas cristalinas de sales de los inhibidores, junto con métodos para preparar las formas cristalinas. Se proporcionan datos de difracción de polvo de rayos X, análisis termogravimétrico, y datos de calorimetría diferencial de barrido de las formas cristalinas. Los inhibidores de integrina son útiles en el tratamiento de, entre otras, las enfermedades fibróticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005889A true MX2023005889A (es) | 2023-06-06 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005889A MX2023005889A (es) | 2020-11-19 | 2021-11-19 | Inhibidor de integrina y usos de este. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12018025B2 (es) |
| EP (1) | EP4247472A1 (es) |
| JP (1) | JP2023550428A (es) |
| KR (1) | KR20230121761A (es) |
| CN (1) | CN116710169A (es) |
| AU (1) | AU2021381516A1 (es) |
| CA (1) | CA3173755A1 (es) |
| CL (1) | CL2023001418A1 (es) |
| CO (1) | CO2023006522A2 (es) |
| CR (1) | CR20230262A (es) |
| CU (1) | CU20230026A7 (es) |
| DO (1) | DOP2023000101A (es) |
| EC (1) | ECSP23045278A (es) |
| IL (1) | IL302651A (es) |
| MX (1) | MX2023005889A (es) |
| PE (1) | PE20240114A1 (es) |
| TW (1) | TW202235417A (es) |
| WO (1) | WO2022109598A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| MX2020014086A (es) | 2018-06-27 | 2021-04-13 | Pliant Therapeutics Inc | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso. |
| WO2024015717A2 (en) * | 2022-07-09 | 2024-01-18 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| WO2018119087A1 (en) | 2016-12-23 | 2018-06-28 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TW201835078A (zh) | 2017-02-28 | 2018-10-01 | 美商萊築理公司 | αvβ6整合蛋白之抑制劑 |
| CA3054792A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
| PL3761980T3 (pl) | 2018-03-07 | 2024-06-10 | Pliant Therapeutics, Inc. | Związki aminokwasowe i sposoby zastosowania |
| MX2020014086A (es) | 2018-06-27 | 2021-04-13 | Pliant Therapeutics Inc | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso. |
| US11521996B2 (en) * | 2018-07-20 | 2022-12-06 | Semiconductor Energy Laboratory Co., Ltd. | Imaging panel comprising a photoelectric conversion element and a first pixel circuit, and imaging device |
| BR112021003859A2 (pt) | 2018-08-29 | 2021-05-18 | Morphic Therapeutic, Inc. | inibindo integrina avss6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047207A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3903316A1 (en) * | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
| US11730144B2 (en) * | 2019-02-15 | 2023-08-22 | Clean Bite, Llc | Oral hygiene appliance |
| SG11202110889WA (en) | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
| EP4058481A1 (en) | 2019-11-15 | 2022-09-21 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| IL297969A (en) * | 2020-05-07 | 2023-01-01 | Pliant Therapeutics Inc | Treatment of respiratory diseases with amino acid compounds |
| TWI838626B (zh) * | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| TW202233224A (zh) * | 2020-10-21 | 2022-09-01 | 美商寇峇有限公司 | 用組合療法治療纖維化之方法 |
| IL308063A (en) | 2021-04-30 | 2023-12-01 | Pliant Therapeutics Inc | Expanded dosing regimens for integrin inhibitors |
| CA3173754A1 (en) | 2021-09-03 | 2024-03-02 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| US20230293519A1 (en) | 2021-10-14 | 2023-09-21 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko unknown
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en active Application Filing
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A1/en active Pending
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en active Pending
-
2023
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022109598A1 (en) | 2022-05-27 |
| US20220177468A1 (en) | 2022-06-09 |
| AU2021381516A1 (en) | 2023-06-22 |
| TW202235417A (zh) | 2022-09-16 |
| CN116710169A (zh) | 2023-09-05 |
| JP2023550428A (ja) | 2023-12-01 |
| KR20230121761A (ko) | 2023-08-21 |
| IL302651A (en) | 2023-07-01 |
| CL2023001418A1 (es) | 2023-10-30 |
| US12018025B2 (en) | 2024-06-25 |
| ECSP23045278A (es) | 2023-07-31 |
| EP4247472A1 (en) | 2023-09-27 |
| DOP2023000101A (es) | 2023-09-29 |
| CU20230026A7 (es) | 2024-01-10 |
| CR20230262A (es) | 2023-07-26 |
| CA3173755A1 (en) | 2022-05-27 |
| CO2023006522A2 (es) | 2023-06-09 |
| PE20240114A1 (es) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005889A (es) | Inhibidor de integrina y usos de este. | |
| MX2020011294A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina. | |
| PH12021551529A1 (en) | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 | |
| MX2022006986A (es) | Inhibidores de kras g12c. | |
| CR20220354A (es) | Inhibidores de egfr | |
| CA2962914C (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| MX2022008456A (es) | Inhibidores de mek y usos terapeuticos de estos. | |
| TN2010000049A1 (en) | Derivatives of n-(arylamino) sulfonamides includig polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same | |
| CR20200620A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer campo | |
| PH12020551853A1 (en) | Axl kinase inhibitors and use of the same | |
| MX2021015935A (es) | Formas de sal de acido bempedoico y metodos para utilizar el mismo. | |
| MY158648A (en) | Compositions for modulating a kinase cascade and methods of use thereof | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| GEP20125433B (en) | α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT | |
| MX2022013401A (es) | Compuestos de azalactama como inhibidores de hpk1. | |
| PH12021550790A1 (en) | Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same | |
| CR20230604A (es) | Inhibidores de mutación de her2 | |
| MX2010010561A (es) | Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos. | |
| MX2021014104A (es) | Formas cristalinas de 5-bromo-2,6-di(1 h-pirazol-1-il)pirimidin-4- amina y nuevas sales. | |
| MX2019012640A (es) | Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa. |